TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis

Angiogenesis

Volumn 16, Issue 3, 2013, Pages 647-662

  Porcù, Elena ^a   Viola, Giampietro ^a   Bortolozzi, Roberta ^a   Persano, Luca ^a   Mitola, Stefania ^b   Ronca, Roberto ^b   Presta, Marco ^b   Romagnoli, Romeo ^c   Baraldi, Pier Giovanni ^c   Basso, Giuseppe ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Angiogenesis; Combretastatin; HUVEC; Vascular disrupting agents; VE cadherin

Indexed keywords

ANGIOGENESIS INHIBITOR; CELL PROTEIN; COMBRETASTATIN A4; CYCLIN DEPENDENT KINASE 1; FOCAL ADHESION KINASE; PROTEIN CDC25C; TR 644; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CAPILLARY TUBE; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CHICK; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MELANOMA; MICROTUBULE ASSEMBLY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CDC25 PHOSPHATASES; CELL CYCLE CHECKPOINTS; CELL MEMBRANE PERMEABILITY; CELL MOVEMENT; CHICK EMBRYO; COLONY-FORMING UNITS ASSAY; CYCLIN B; ENDOTHELIAL CELLS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FOCAL ADHESION KINASE 1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; THIAZOLES;

MUS;

EID: 84879209616     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-013-9343-z     Document Type: Article

References (43)

1. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265
2. Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790-803
3. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumor blood vessel. Nat Rev Cancer 5:423-435
4. Schwartz EL (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15:2594-2601
5. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318-1327
6. Gaukroger K, Hadfield JA, Lawrence NJ, Nlan S, McGown AT (2003) Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit? Org Biomol Chem 1:3033-3037
7. Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA (2006) Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 49:3033-3044
8. Wang L, Woods KW, Li Q, Barr KJ, McCroskey RW, Hannick SM, Gherke L, Credo RB, Hui YH, Marsh K, Warner R, Lee JY, Zielinski-Mozng N, Frost D, Rosenberg SH, Sham HL (2002) Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem 45:1697-1711
9. Schobert R, Biersack B, Dietrich A, Effenberger K, Knauer S, Mueller T (2010) 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cis platin resistant germ cell tumor model. J Med Chem 53:6595-6602
10. Ohsumi K, Hatanaka T, Fujita K, Nakagawa R, Fukuda Y, Nihai Y, Suga Y, Morinaga Y, Akiyama Y, Tsuji T (1988) Synthesis and antitumor activity of cis-restricted combretastatins 5-membered heterocyclic analogues. Bioorg Med Chem Lett 8:3153-3158
11. Tron GC, Pagliai F, Del Grosso E, Genazzani AA, Sorba G (2005) Synthesis and cytotoxic evaluation of combretafurazans. J Med Chem 48:3260-3268
12. Liu T, Dong X, Xue N, Wu R, He Q, Yang B, Hu Y (2009) Synthesis and biological evaluation of 3,4-biaryl-5-aminoisoxazole derivatives. Bioorg Med Chem 17:6279-6285
13. Wu M, Li W, Yang C, Chen D, Ding J, Chen Y, Lin L, Xie Y (2007) Synthesis and activity of combretastatin A-4 analogues: 1,2,3-thiadiazoles as potent antitumor agents. Bioorg Med Chem Lett 17:869-873
14. Romagnoli R, Baraldi PG, Cruz-Lopez O, Lopez-Cara C, Carrion MD, Brancale A, Hamel E, Chen L, Bortolozzi R, Basso G, Viola G (2010) Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogs. J Med Chem 53:4248-4258
15. Romagnoli R, Baraldi PG, Brancale A, Ricci A, Hamel E, Bortolozzi R, Basso G, Viola G (2011) Convergent synthesis and biological evaluation of 2-amino-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents. J Med Chem 54:5144-5153
16. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experentia 45:209-211
17. Pettit GR, Temple C Jr, Narayanan VL, Varma R, Boyd MR, Rener GA, Bansal N (1995) Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10:299-309
18. Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, Hogan F (1985) Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J Med Chem 38:1666-1672
19. Mitola S, Strasly M, Prato M, Ghia P, Bussolino F (2003) IL-12 regulates an endothelial cell-lymphocyte network: effect on metalloproteinase-9 production. J Immunol 171:3725-3733
20. Basili S, Basso G, Faccio A, Granzhan A, Ihmels H, Moro S, Viola G (2008) Diazoniapolycyclic ions inhibit activity of topoisomerase I and growth of certain tumor cell lines. ChemMedChem 3:1671-1676
21. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2:329-333
22. Guidolin D, Vacca A, Nussdorfer GG, Ribatti D (2004) A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc Res 67:117-124
23. Viola G, Fortunato E, Cecconet L, Del Giudice L, Dall'Acqua F, Basso G (2008) Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544. Toxicol Appl Pharmacol 227:84-96
24. Chiodelli P, Mitola S, Ravelli C, Oreste P, Rusnati M, Presta M (2011) Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterioscler Thromb Vasc Biol 31:e116-e127
25. Dejana E, Giampietro C (2012) Vascular endothelial-cadherin and vascular stability. Curr Opin Hematol 19:218-223
26. Vittet D, Buchou T, Schweitzer A, Dejana E, Huber P (1997) Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies. Proc Natl Acad Sci USA 94:6273-6278
27. Feraud O, Cao Y, Vittet D (2001) Embryonic stem cell-derived embryoid bodies development in collagen gels recapitulates sprouting angiogenesis. Lab Invest 81:1669-1681
28. Dejana E, Orsenigo F, Lampugnani MG (2008) The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 121:2115-2122
29. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992-3006
30. Bogatcheva NV, Verin AD (2008) The role of cytoskeleton in the regulation of vascular endothelial barrier function. Microvasc Res 76:202-207
31. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6:56-68
32. Herzog B, Pellet-Many C, Britton G, Hartzoulakis B, Zachary IC (2011) VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Mol Biol Cell 22:2766-2776
33. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh DA, Schlaepfer DD (2012) VEGF-induced vascular permeability is mediated by FAK. Dev Cell 22:146-157
34. Andrés G, Leali D, Mitola S, Coltrini D, Camozzi M, Corsini M, Belleri M, Hirsch E, Schwendener RA, Christofori G, Alcamí A, Presta M (2009) A pro-inflammatory signature mediates FGF2-induced angiogenesis. J Cell Mol Med 13:2083-2108
35. Atherton-Fessler S, Liu F, Gabrielli B, Lee MS, Peng CY, Piwnica-Worms H (1994) Cell cycle regulation of the p34cdc2 inhibitory kinases. Mol Biol Cell 5:989-1001
36. Choi HJ, Fukui M, Zhu BT (2012) Role of cyclin B1/Cdc2 up-regulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazole. PLoS One 6:e24312
37. Mollinedo F, Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8:413-450
38. Lu H, Murtagh J, Schwartz EL (2006) The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol Pharmacol 69:1207-1215
39. Murtagh J, Lu H, Schwartz EL (2006) Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation. Cancer Res 66:8192-8199
40. Qin L, Zhang M (2010) Maspin regulates endothelial cell adhesion and migration through an integrin signaling pathway. J Biol Chem 285:32360-32369
41. Dalyot-Herman N, Delgado-Lopez F, Gewirtz DA, Gupton JT, Schwartz EL (2009) Interference with endothelial cell function by JG-03-14, an agent that binds to the colchicine site on microtubules. Biochem Pharmacol 78:1167-1177
42. Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, Trusk P, Lyass A, Rechavi G, Spector NL, Lo SH, Schmitt F, Bacus SS, Yarden Y (2007) A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 9:961-969
43. Presta M, Andrés G, Leali D, Dell'Era P, Ronca R (2009) Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. Eur Cytokine Netw 20:39-50